Want to see ADAPY full AI Analyst Report?
Adaptimmune Therapeutics (ADAPY) Ratios
Adaptimmune Therapeutics Ratios
ADAPY's free cash flow for Q2 2025 was $-34.85M. For the 2025 fiscal year, ADAPY's free cash flow was decreased by $-75.00K and operating cash flow was $-34.78M. See a summary of the company’s cash flow.
| Ratios | Dec 24 | Dec 23 | Dec 22 | Dec 21 | Dec 20 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.92 | 2.85 | 3.96 | 6.64 | 10.19 |
| Quick Ratio | 2.80 | 2.85 | 3.96 | 6.64 | 10.19 |
| Cash Ratio | 1.41 | 1.98 | 1.67 | 2.40 | 1.46 |
| Solvency Ratio | -0.25 | -0.43 | -0.65 | -0.57 | -1.11 |
| Operating Cash Flow Ratio | -1.13 | -1.94 | -2.20 | 0.17 | -1.37 |
| Short-Term Operating Cash Flow Coverage | -15.55 | 0.00 | -51.97 | 4.62 | 0.00 |
| Net Current Asset Value | $ -45.95M | $ -35.55M | $ 8.33M | $ 151.87M | $ 288.24M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.30 | 0.09 | 0.07 | 0.05 | 0.05 |
| Debt-to-Equity Ratio | 6.26 | 0.64 | 0.28 | 0.12 | 0.07 |
| Debt-to-Capital Ratio | 0.86 | 0.39 | 0.22 | 0.11 | 0.06 |
| Long-Term Debt-to-Capital Ratio | 0.81 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 20.76 | 7.15 | 4.02 | 2.28 | 1.32 |
| Debt Service Coverage Ratio | -6.98 | 0.00 | -57.95 | -67.44 | 0.00 |
| Interest Coverage Ratio | -20.54 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.40 | 0.00 | 0.01 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.31 | 0.13 | 0.14 | 0.16 | 0.17 |
| Net Debt to EBITDA | 0.32 | 0.93 | 0.55 | 0.80 | 0.26 |
| Profitability Margins | |||||
| Gross Profit Margin | 99.96% | 83.65% | -370.48% | -1706.64% | -2213.49% |
| EBIT Margin | -35.89% | -228.99% | -595.51% | -2638.58% | -3370.52% |
| EBITDA Margin | -29.58% | -212.67% | -573.13% | -2531.78% | -3178.65% |
| Operating Profit Margin | -38.62% | -228.99% | -603.97% | -2638.58% | -3370.52% |
| Pretax Profit Margin | -37.78% | -186.68% | -600.26% | -2558.12% | -3282.72% |
| Net Profit Margin | -39.78% | -188.90% | -609.46% | -2570.99% | -3286.81% |
| Continuous Operations Profit Margin | -39.79% | -188.90% | -609.46% | -2570.99% | -3286.81% |
| Net Income Per EBT | 105.27% | 101.19% | 101.53% | 100.50% | 100.12% |
| EBT Per EBIT | 97.83% | 81.52% | 99.39% | 96.95% | 97.40% |
| Return on Assets (ROA) | -28.79% | -40.29% | -50.30% | -33.67% | -28.84% |
| Return on Equity (ROE) | -597.64% | -288.19% | -202.08% | -76.76% | -38.12% |
| Return on Capital Employed (ROCE) | -37.90% | -65.79% | -62.01% | -39.86% | -32.37% |
| Return on Invested Capital (ROIC) | -36.03% | -64.14% | -60.76% | -39.41% | -32.16% |
| Return on Tangible Assets | -29.25% | -40.34% | -50.37% | -33.74% | -28.95% |
| Earnings Yield | -52.10% | -71.41% | -70.30% | -27.06% | -16.94% |
| Efficiency Ratios | |||||
| Receivables Turnover | 11.14 | 1.28 | 0.71 | 0.18 | 0.19 |
| Payables Turnover | 0.01 | 1.21 | 26.87 | 13.69 | 14.33 |
| Inventory Turnover | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 3.48 | 0.84 | 0.38 | 0.12 | 0.08 |
| Asset Turnover | 0.72 | 0.21 | 0.08 | 0.01 | 0.01 |
| Working Capital Turnover Ratio | 1.38 | 0.37 | 0.10 | 0.02 | 0.02 |
| Cash Conversion Cycle | -7121.23 | -16.88 | 498.49 | 1991.97 | 1885.66 |
| Days of Sales Outstanding | 32.77 | 284.09 | 512.07 | 2018.63 | 1911.13 |
| Days of Inventory Outstanding | 38168.57 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 45322.57 | 300.97 | 13.58 | 26.66 | 25.47 |
| Operating Cycle | 38201.34 | 284.09 | 512.07 | 2018.63 | 1911.13 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.29 | -0.70 | -0.88 | 0.07 | -0.38 |
| Free Cash Flow Per Share | -0.30 | -0.72 | -1.06 | 0.01 | -0.40 |
| Dividend Paid and CapEx Coverage Ratio | -26.91 | -28.87 | -4.77 | 1.22 | -18.44 |
| Capital Expenditure Coverage Ratio | -26.91 | -28.87 | -4.77 | 1.22 | -18.44 |
| Operating Cash Flow Coverage Ratio | -0.99 | -5.58 | -6.14 | 0.42 | -2.26 |
| Operating Cash Flow to Sales Ratio | -0.41 | -2.34 | -5.22 | 1.74 | -13.54 |
| Free Cash Flow Yield | -55.86% | -91.41% | -72.87% | 0.33% | -7.36% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -1.92 | -1.40 | -1.42 | -3.70 | -5.90 |
| Price-to-Sales (P/S) Ratio | 0.76 | 2.65 | 8.67 | 95.02 | 194.01 |
| Price-to-Book (P/B) Ratio | 11.47 | 4.04 | 2.87 | 2.84 | 2.25 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -1.79 | -1.09 | -1.37 | 299.93 | -13.59 |
| Price-to-Operating Cash Flow Ratio | -1.86 | -1.13 | -1.66 | 54.46 | -14.33 |
| Price-to-Earnings Growth (PEG) Ratio | 0.04 | 0.03 | 0.00 | -0.28 | 0.19 |
| Enterprise Value Multiple | -2.26 | -0.32 | -0.97 | -2.95 | -5.84 |
| Enterprise Value | 118.98M | 40.70M | 150.41M | 459.79M | 734.71M |
| EV to EBITDA | -2.26 | -0.32 | -0.97 | -2.95 | -5.84 |
| EV to Sales | 0.67 | 0.68 | 5.54 | 74.77 | 185.63 |
| EV to Free Cash Flow | -1.57 | -0.28 | -0.88 | 236.03 | -13.00 |
| EV to Operating Cash Flow | -1.63 | -0.29 | -1.06 | 42.85 | -13.71 |
| Tangible Book Value Per Share | 0.03 | 0.19 | 0.51 | 1.32 | 2.38 |
| Shareholders’ Equity Per Share | 0.05 | 0.20 | 0.51 | 1.32 | 2.40 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.05 | -0.01 | -0.02 | -0.01 | -0.00 |
| Revenue Per Share | 0.71 | 0.30 | 0.17 | 0.04 | 0.03 |
| Net Income Per Share | -0.28 | -0.57 | -1.03 | -1.01 | -0.91 |
| Tax Burden | 1.05 | 1.01 | 1.02 | 1.01 | 1.00 |
| Interest Burden | 1.05 | 0.82 | 1.01 | 0.97 | 0.97 |
| Research & Development to Revenue | 0.84 | 2.10 | 4.70 | 18.07 | 23.13 |
| SG&A to Revenue | 0.46 | 1.19 | 2.33 | 9.32 | 11.57 |
| Stock-Based Compensation to Revenue | 0.07 | 0.20 | 0.67 | 3.35 | 2.63 |
| Income Quality | 1.03 | 1.24 | 0.86 | -0.07 | 0.41 |
Currency in USD
